Inactive Instrument

News Biocorrx Inc Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

All News

09-10	Biocorrx Inc Announces Appointment of Richard J. Baum to Strategic Advisory Board	CI
09-04	BioCorRx Inc. Announces Resignation of Kate Beebe Devarney as Member of the Board of Directors, Effective August 31, 2026	CI
08-14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
01-06	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
12-10	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
11-15	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/07/25	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
16/05/25	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/03/25	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
14/11/24	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
15/08/24	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
14/08/24	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
16/05/24	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
15/05/24	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04/04/24	BioCorRx Inc. Announces Board Resignations	CI
03/04/24	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
02/04/24	BioCorRx Reports Business Update for 2023	AQ
02/04/24	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01/04/24	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
28/02/24	BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	AQ